Potential Malaria Vaccine Disappoints in New Trial

A recent clinical trial involving African infants ages 6–12 weeks revealed that a potential malaria vaccine was only 30% effective in reducing episodes of the disease, Reuters reports. The mosquito-borne illness infected about 216 million people worldwide in 2010. Other control measures such as insecticide-treated bug netting have decreased malaria-related deaths in recent years, and scientists hoped that the vaccine, known as RTS,S or Mosquirix, would continue to cut infection and mortality rates. Philanthropist and Microsoft co-founder Bill Gates helped fund the development, and calls for further research. If effective, the vaccine would likely be added to routine infant immunizations in the most-impacted countries.

Image: Newborn via Shutterstock. 

Comments

Be the first to comment!


All Topics in Parents News Now


Parents may receive compensation when you click through and purchase from links contained on this website.